Company
Amplia Therapeutics Ltd
ASX:ATX
Amplia Therapeutics Limited is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF).
39 stories
Amplia Therapeutics data confirms potential of drug candidate in treating acute myeloid leukemia
“The impressive results we are reporting tell us that there may be a clinical rationale to include AMP886 as part of new treatment regimens for unmet needs in AML," CEO Dr John Lambert said.
Amplia Therapeutics seeks new CEO to "take company to the next stage"
“We will be seeking to identify a new CEO with the ability to build on the established clinical development capability and to take the company to its next stage," Amplia Therapeutics chair Dr Warwick Tong said.
Amplia Therapeutics receives $1.8 million R&D refund for cancer inhibitor studies
The company is advancing a pipeline of FAK inhibitors for cancer and fibrosis and has received an R&D tax incentive refund.
Amplia Therapeutics recruits first patient to ACCENT trial in pancreatic cancer
“This is another exciting milestone marking the achievements and growth of our company and we’re very proud of our team’s efforts in starting up the ACCENT trial,” said MD/CEO Dr John Lambert.
FIVE at FIVE AU: Travel stocks back despite travel havoc, oil price down and Atlassian founders (not those ones) make their own energy play
Kim Jackson says the consortium sees "strong promise in Genex’s portfolio and together the Skip Essential Infrastructure Fund and Stonepeak bring the experience and insight required to allow Genex to play a substantially larger role in Aust
Amplia Therapeutics has abstract accepted for major pancreatic cancer conference
A presentation on the ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer will be made at the American Association for Cancer Research Special Conference on Pancreatic Cancer in September.
Amplia Therapeutics’ inhibitor AMP945 shows comparable efficacy to existing treatment for idiopathic pulmonary fibrosis
“These new results reconfirm the efficacy of AMP945 in the industry-standard preclinical IPF model and show that, in a head-to-head comparison, the activity of AMP945 is comparable to the current market leader, OFEV®,” says CEO and MD Dr Jo
Amplia Therapeutics secures second ethics clearance for Phase 2 AMP945 pancreatic cancer trial
“Our focus is now on timely recruitment and execution of a high-quality trial that will support our future development plans for AMP945 in this very dangerous disease," says MD Dr John Lambert.
Amplia Therapeutics receives positive FDA feedback on proposed clinical study for AMP945 in people with pancreatic cancer
“This pre-IND advice provides early insight into FDA’s priorities and equips us to address these proactively. It also allows us to enter our planned clinical study reassured that our intent to bring first-line patients into the trial is rea
Amplia Therapeutics cleared to begin Phase 2 clinical trial in pancreatic cancer patients
“Today is a very exciting day for Amplia and we welcome the HREC’s clearance to commence the first clinical trial of AMP945 in pancreatic cancer patients,” Amplia’s CEO and managing director Dr John Lambert said.
Amplia Therapeutics' latest results suggest candidate improves survival in human pancreatic cancer model
“These data are particularly compelling as AMP945 has been used to treat tumours that have formed from human pancreatic cancer cells. Aside from actually running the clinical trial, this is the most compelling translational evidence we coul
Amplia Therapeutics' AMP945 shown to improve effectiveness of gemcitabine/Abraxane® in human pancreatic cancer
Researchers at the Garvan Institute have shown that the addition of AMP945 pre-treatment to a gemcitabine/Abraxane® chemotherapy regimen increased survival by 33%.
Amplia Therapeutics to showcase clinical data at major cancer conference
“The AACR is one of the most recognised international forums for cancer research and we are delighted that the results of our phase one trial have been selected for presentation at this prestigious meeting,” says CEO.
Amplia Therapeutics well placed for pipeline progression in the new year
“While 2021 was a challenging year for everyone, I am extremely proud of what our team at Amplia has been able to achieve. In the last quarter of 2021, we put in place all the elements to make 2022 a watershed year for the company," says CE
ASX up, gas volatility in 2022 and Crown shareholders are happy
Wood Mackenzie vice president Massimo Do Odoardo says that while the market will stay resilient in the short term, high prices will pressure demand and the rationale for China to switch from coal to gas will diminish.
Amplia Therapeutics completes AMP945 manufacturing run ahead of phase two clinical trials
The batch was produced on time and within budget and represents a big step up from the 1-kilogram batch that’s been manufactured under GMP conditions previously.
Amplia Therapeutics looks to build on clinical momentum in 2022
“Our priorities for 2022 are clear – our goal will be to build on the solid foundations of the last 12 months and maintain this momentum as we move towards two phase-two trials in the new year,” says CEO.
Amplia Therapeutics scores A$2.1 million Victorian Government research and development funding facility
The low-interest Victorian Government loan scheme is designed to support small and medium enterprises investing in technologies deemed vital to the state's future growth.
Amplia Therapeutics drug candidates make further strides toward cancer and fibrotic diseases treatment
Amplia has designed a Phase 2 clinical trial of AMP945 in pancreatic cancer patients and plans to initiate patient recruitment at Australian sites in the first quarter of calendar 2022.
Amplia Therapeutics' Phase 1 clinical trial shows AMP945 is safe and well tolerated at all doses tested
The company is optimistic about the results of its Phase 1 clinical trial with results supporting further development of AMP945 as a treatment for cancer and fibrosis.
Amplia Therapeutics' new data reveals inhibition of Focal Adhesion Kinase in humans
The data will be used to further refine the doses of AMP945 to be used in a Phase 2 clinical trial in patients with pancreatic cancer and will provide guidance for the Phase 2 trial in pulmonary fibrosis planned for the second half of 2022.
Amplia Therapeutics seeking A$12.4 million to progress pancreatic cancer clinical trial
Proceeds from the placement and entitlement offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies.
Amplia Therapeutics and CRUK agree to amend licence terms for FAK asset AMP886
The company has also entered a trading halt as it undertakes a capital-raising process. The halt is in place until Monday, November 8, or when an announcement is released to the market.
Amplia Therapeutics appoints pharmaceutical veteran as clinical advisor
José Iglesias MD will join the ATX team as a clinical advisor, providing more than 30 years of experience in the pharmaceutical industry.
Amplia Therapeutics receives million dollar Research and Development Tax Incentive Refund
The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.
Amplia Therapeutics appoints Bio101’s Hamish George as chief financial officer
George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years.
The ASX-listed biotech companies hoping to improve the lives of cancer patients
Cancer is estimated to cost nearly US$1 trillion worldwide every year, but a small group of ASX biotech stocks is working to change that.
Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.
Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar
Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.
Lifescience innovators to feature in Proactive Lifesciences Webinar next Tuesday
Join three emerging lifescience companies as they present their investment cases at Proactive's Lifesciences Webinar at 12pm AEST on Tuesday, September 28, 2021.
Amplia Therapeutics shifts from pre-clinical to drug development with two potent candidates for cancer and fibrotic diseases treatment
It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases.
Amplia Therapeutics to conduct Phase 2 trial for Focal Adhesion Kinase inhibitor AMP945 in first line pancreatic cancer patients
The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.